NASDAQ:RUBYRubius Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rubius Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.18 +0.01 (+0.19 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$5.01Now: $5.18▼$5.1950-Day Range$4.91MA: $5.87▼$6.6352-Week Range$3.35Now: $5.18▼$14.44Volume102,836 shsAverage Volume138,527 shsMarket Capitalization$416.89 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingRubius Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Rubius Therapeutics has a potential upside of 93.1% from its current price of $5.18.Amount of Analyst CoverageRubius Therapeutics has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesRubius Therapeutics has received 160 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRubius Therapeutics has received 188 “underperform” votes. (Add your “underperform” vote.)Community SentimentRubius Therapeutics has received 54.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote “Outperform” if you believe RUBY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRubius Therapeutics does not currently pay a dividend.Dividend GrowthRubius Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rubius Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders58.40% of the stock of Rubius Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.99% of the stock of Rubius Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rubius Therapeutics are expected to grow in the coming year, from ($2.06) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rubius Therapeutics is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rubius Therapeutics is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRubius Therapeutics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RUBY Previous Symbol CUSIPN/A CIKN/A Webwww.rubiustx.com Phone617-679-9600Debt Debt-to-Equity Ratio0.36 Current Ratio8.99 Quick Ratio8.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book1.51Profitability EPS (Most Recent Fiscal Year)($2.08) Net Income$-163,460,000.00 Net MarginsN/A Return on Equity-61.83% Return on Assets-44.47%Miscellaneous Employees142 Outstanding Shares80,480,000Market Cap$416.89 million Next Earnings Date8/10/2020 (Confirmed) OptionableNot Optionable $5.18 +0.01 (+0.19 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RUBY News and Ratings via Email Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter. Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions How has Rubius Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RUBY shares have decreased by 20.9% and is now trading at $5.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Rubius Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Rubius Therapeutics. When is Rubius Therapeutics' next earnings date? Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Rubius Therapeutics. How were Rubius Therapeutics' earnings last quarter? Rubius Therapeutics Inc (NASDAQ:RUBY) released its earnings results on Monday, May, 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.04. View Rubius Therapeutics' earnings history. What price target have analysts set for RUBY? 6 analysts have issued twelve-month price objectives for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $28.00. On average, they anticipate Rubius Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price. View analysts' price targets for Rubius Therapeutics. Has Rubius Therapeutics been receiving favorable news coverage? Headlines about RUBY stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rubius Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Rubius Therapeutics. Who are some of Rubius Therapeutics' key competitors? Some companies that are related to Rubius Therapeutics include Sangamo Therapeutics (SGMO), Legend Biotech (PCVX), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Regenxbio (RGNX), Beam Therapeutics (BEAM), Cortexyme (CRTX), Coherus Biosciences (CHRS), Alector (ALEC), Compugen (CGEN), I-Mab (BDTX), Adaptimmune Therapeutics (ADAP) and Nantkwest (NK). View all competitors. What other stocks do shareholders of Rubius Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Opko Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Dicerna Pharmaceuticals (DRNA), Editas Medicine (EDIT) and Amicus Therapeutics (FOLD). Who are Rubius Therapeutics' key executives? Rubius Therapeutics' management team includes the following people: Mr. David R. Epstein, Exec. Chairman (Age 57)Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)Mr. Andrew M. Oh, Chief Financial Officer (Age 47)Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50) When did Rubius Therapeutics IPO? (RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO. What is Rubius Therapeutics' stock symbol? Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY." Who are Rubius Therapeutics' major shareholders? Rubius Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Swiss National Bank (0.09%), Virtus ETF Advisers LLC (0.07%), Russell Investments Group Ltd. (0.06%), SG Americas Securities LLC (0.05%), Trexquant Investment LP (0.04%) and ProShare Advisors LLC (0.02%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen. View institutional ownership trends for Rubius Therapeutics. Which institutional investors are selling Rubius Therapeutics stock? RUBY stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, and Robert Langer. View insider buying and selling activity for Rubius Therapeutics. Which institutional investors are buying Rubius Therapeutics stock? RUBY stock was acquired by a variety of institutional investors in the last quarter, including Virtus ETF Advisers LLC, Trexquant Investment LP, State Board of Administration of Florida Retirement System, Swiss National Bank, SG Americas Securities LLC, Principal Financial Group Inc., and ProShare Advisors LLC. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni. View insider buying and selling activity for Rubius Therapeutics. How do I buy shares of Rubius Therapeutics? Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Rubius Therapeutics' stock price today? One share of RUBY stock can currently be purchased for approximately $5.18. How big of a company is Rubius Therapeutics? Rubius Therapeutics has a market capitalization of $416.89 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe. What is Rubius Therapeutics' official website? The official website for Rubius Therapeutics is www.rubiustx.com. How can I contact Rubius Therapeutics? Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
